Emisphere Technologies, Inc. (NASDAQOTH:EMIS)

CAPS Rating: 1 out of 5 2.50

A biopharmaceutical company specializing in the oral delivery of therapeutic macromolecules and other compounds that are poorly deliverable by oral means.

Caps

How do you think EMIS will perform against the market?

Add Stock to CAPS Watchlist

All Players

52 Outperform
50 Underperform
 

All-Star Players

8 Outperform
26 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top EMIS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

rajny (< 20)
Submitted October 21, 2010

I can't argue with the thumbs-down pitches. This stock has held promise and has disappointed for years.However, if someone is looking for a high-risk, potentially high reward stock, EMIS is the biotech to look at...especially because it has been… More

TSIF (99.98)
Submitted February 11, 2019

May have some potential working with Novo Nordisk on applying their technology to oral insulin, but the low overhead from the (six) cited employees is being offset by the very high debt load. Data/Filings look stale, but last posted they had a neg… More

EMIS VS S&P 500 (SPY)

Fools bullish on EMIS are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about EMIS.

Recs

0
Member Avatar Paco57 (23.39) Submitted: 3/17/2019 9:27:20 PM : Outperform Start Price: $8.20 EMIS Score: -28.45

Sleeper.

Recs

0
Member Avatar kdakota630 (29.35) Submitted: 2/22/2019 10:32:37 AM : Underperform Start Price: $3.05 EMIS Score: -86.90

Whoa, Nellie, not so fast fella. No way! Back to reality. Not a good pick. Not now. Wrong logic at this point. Gravity calls. Watch out on this one. Not at all optimistic. Pessimism reigns. Downward trend continues. Likely to continue to underperform. Look out below. More downside imminent. Danger danger, at least for the next month. So obvious.

Recs

2
Member Avatar TSIF (99.98) Submitted: 2/11/2019 1:17:18 PM : Underperform Start Price: $3.40 EMIS Score: -68.33

May have some potential working with Novo Nordisk on applying their technology to oral insulin, but the low overhead from the (six) cited employees is being offset by the very high debt load.
Data/Filings look stale, but last posted they had a
neg -155M in book, they aren't worth a $200M Market cap.

OTC company.

Target 20+ points

Leaderboard

Find the members with the highest scoring picks in EMIS.

Score Leader

MATTEH

MATTEH (81.23) Score: +281.41

The Score Leader is the player with the highest score across all their picks in EMIS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
MATTEH 81.23 9/20/2010 Outperform 5Y $1.10 +427.27% +145.86% +281.41 0 Comment
rajny < 20 10/19/2010 Outperform 5Y $1.17 +395.73% +137.05% +258.67 1 Comment
Pilarchard 96.81 10/23/2006 Underperform 5Y $9.98 -41.88% +115.87% +157.76 0 Comment
astrodogind 92.36 10/16/2006 Underperform 5Y $9.66 -39.96% +117.12% +157.08 4 Comments
runway2 < 20 3/21/2011 Outperform 1Y $1.60 +262.50% +115.17% +147.33 0 Comment
bwedeking 73.31 10/30/2006 Underperform NS $7.20 -19.44% +115.39% +134.84 0 Comment
TMFNosediveflip 97.50 10/31/2006 Underperform 1Y $6.86 -15.45% +114.62% +130.07 0 Comment
msonif < 20 11/3/2006 Underperform 3W $5.99 -3.17% +115.92% +119.10 0 Comment
h20diver < 20 11/3/2006 Underperform 3W $5.58 +3.94% +116.24% +112.30 0 Comment
bush08hal 71.99 11/29/2006 Underperform NS $5.50 +5.45% +112.40% +106.94 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackIcahn 86.33 8/27/2008 Outperform 1Y $3.85 +50.65% +125.89% -75.24 1 Comment
TrackMatrix < 20 9/1/2006 Underperform NS $8.30 -95.78% +5.87% +101.65 4/17/2012 @ $0.35 0 Comment

Advertisement